Management of Helicobacter pylori Infection: A Comparison between Korea and the United States
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Helicobacter pylori has been well known to cause gastritis, peptic ulcers, mucosa-associated lymphoid tissue, and gastric cancer. The importance of H. pylori eradication has been emphasized; however, the management of H. pylori infection is difficult in clinical practice. In both Eastern and Western countries, there has been a constant interest in confirming individuals who should be tested and treated for H. pylori infection and developing methods to diagnose H. pylori infection. Many studies have been implemented to successfully eradicate H. pylori, and various combinations of eradication regimens for H. pylori infection have been suggested worldwide. Based on the findings of previous studies, a few countries have published their own guidelines that are appropriate for their country; however, these country-specific guidelines may differ depending on the circumstances in each country. Evidence-based guidelines and clinical practice updates for the treatment of H. pylori infection have been published in Korea and the United States in 2021. This review will summarize the similarities and differences in the management of H. pylori infection in Korea and the United States, focusing on indications, diagnosis, and treatments based on recent guidelines and recommendations in both countries.
Abstract
Helicobacter pylori has been well known to cause gastritis, peptic ulcers, mucosa-associated lymphoid tissue, and gastric cancer. The importance of H. pylori eradication has been emphasized; however, the management of H. pylori infection is difficult in clinical practice. In both Eastern and Western countries, there has been a constant interest in confirming individuals who should be tested and treated for H. pylori infection and developing methods to diagnose H. pylori infection. Many studies have been implemented to successfully eradicate H. pylori, and various combinations of eradication regimens for H. pylori infection have been suggested worldwide. Based on the findings of previous studies, a few countries have published their own guidelines that are appropriate for their country; however, these country-specific guidelines may differ depending on the circumstances in each country. Evidence-based guidelines and clinical practice updates for the treatment of H. pylori infection have been published in Korea and the United States in 2021. This review will summarize the similarities and differences in the management of H. pylori infection in Korea and the United States, focusing on indications, diagnosis, and treatments based on recent guidelines and recommendations in both countries.
참고문헌 (38)
- IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, "Biological agents. Volume 100 B. A review of human carcinogens", IARC Monogr Eval Carcinog Risks Hum, 100(Pt B), pp.1~441 (2012)
- Savoldi A, "Prevalence of antibiotic resistance in Helicobacter pylori : a systematic review and meta-analysis in World Health Organization regions", Gastroenterology, 155, pp.1372~1382 (2018)
- "WHO publishes list of bacteria for which new antibiotics are urgently needed" (2017)[URL]
- Jung Hye-Kyung, "Evidence-Based Guidelines for the Treatment of Helicobacter pylori Infection in Korea 2020", Gut and Liver, 15(2), pp.168~195 (2021), 거트앤리버 소화기연관학회협의회[DOI]
- Shah SC, "AGA clinical practice update on the management of refractory Helicobacter pylori infection : expert review", Gastroenterology, 160, pp.1831~1841 (2021)
- Chey WD, "ACG clinical guideline : treatment of Helicobacter pylori infection", Am J Gastroenterol, 112, pp.212~239 (2017)
- El-Serag HB, "Houston Consensus Conference on testing for Helicobacter pylori infection in the United States", Clin Gastroenterol Hepatol, 16, pp.992~1002 (2018)
- 김나영, "헬리코박터 파일로리 감염의 진단 및 치료 가이드라인", 대한소화기학회지, 54(5), pp.269~278 (2009), 대한소화기학회
- Kim SG, "Guidelines for the diagnosis and treatment of Helicobacter pylori infection in Korea, 2013 revised edition", J Gastroenterol Hepatol, 29, pp.1371~1386 (2014)
- Lee SY, "Current progress toward eradicating Helicobacter pylori in East Asian countries : differences in the 2013 revised guidelines between China, Japan, and South Korea", World J Gastroenterol, 20, pp.1493~1502 (2014)
- Hiroi S, "Impact of health insurance coverage for Helicobacter pylori gastritis on the trends in eradication therapy in Japan : retrospective observational study and simulation study based on real-world data", BMJ Open, 7, pp.e015855~ (2017)
- Lee HJ, "Eradication of Helicobacter pylori according to 23S ribosomal RNA point mutations associated with clarithromycin resistance", J Infect Dis, 208, pp.1123~1130 (2013)
- Tae-Geun Gweon, "An Economic Modeling Study of Helicobacter pylori Eradication: Comparison of Dual Priming Oligonucleotide-Based Multiplex Polymerase Chain Reaction and Empirical Treatment", Gut and Liver, 12(6), pp.648~654 (2018), 거트앤리버 소화기연관학회협의회
- Cho JH, "Cost-effectiveness of a tailored Helicobacter pylori eradication strategy based on the presence of a 23S ribosomal RNA point mutation that causes clarithromycin resistance in Korean patients", J Gastroenterol Hepatol, 34, pp.700~706 (2019)
- Malfertheiner P, "Management of Helicobacter pylori infection : the Maastricht V", Florence Consensus Report, 2017, pp.66, 6~30
- Lee JH, "Nationwide antibiotic resistance mapping of Helicobacter pylori in Korea : a prospective multicenter study", Helicobacter, 24, pp.e12592~ (2019)
- Lee JY, "Primary and secondary antibiotic resistance of Helicobacter pylori in Korea from 2003 to 2018", Helicobacter, 24, pp.e12660~ (2019)
- Lee Jung Won, "Efficacy of Tegoprazan for Improving the Susceptibility of Antimicrobial Agents against Antibiotic-Resistant Helicobacter pylori", Gut and Liver, 15(1), pp.53~60 (2021), 거트앤리버 소화기연관학회협의회[DOI]
- Kim BJ, "Online registry for nationwide database of Helicobacter pylori eradication in Korea : correlation of antibiotic use density with eradication success", Helicobacter, 24, pp.e12646~ (2019)
- 배현진, "Concomitant or Sequential Therapy as the First-line Therapy for Eradication of Helicobacter pylori Infection in Korea: A Systematic Review and Meta-analysis", 대한소화기학회지, 71(1), pp.31~37 (2018), 대한소화기학회[DOI]
- Beom Jin Kim, "Ten-Day Concomitant, 10-Day Sequential, and 7-Day Triple Therapy as First-Line Treatment for Helicobacter pylori Infection: A Nationwide Randomized Trial in Korea", Gut and Liver, 13(5), pp.531~540 (2019), 거트앤리버 소화기연관학회협의회[DOI]
- 공은정, "Meta-Analysis of First-Line Triple Therapy for Helicobacter pylori Eradication in Korea: Is It Time to Change?", Journal of Korean Medical Science, 29(5), pp.704~713 (2014), 대한의학회
- Chey WD, "American College of Gastroenterology guideline on the management of Helicobacter pylori infection", Am J Gastroenterol, 102, pp.1808~1825 (2007)
- Bray F, "Global cancer statistics 2018 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185countries", CA Cancer J Clin, 68, pp.394~424 (2018)
- Choi IJ, "Family history of gastric cancer and Helicobacter pylori treatment", N Engl J Med, 382, pp.427~436 (2020)
- Theel ES, "Use of the Optum Labs Data Warehouse to assess test ordering patterns for diagnosis of Helicobacter pylori infection in the United States", J Clin Microbiol, 53, pp.1358~1360 (2015)
- Jun JK, "Effectiveness of the Korean National Cancer Screening Program in reducing gastric cancer mortality", Gastroenterology, 152, pp.1319~1328 (2017)
- Marrero Rolon R, "Clinical evaluation of a real-time PCR assay for simultaneous detection of Helicobacter pylori and genotypic markers of clarithromycin resistance directly from stool", J Clin Microbiol, 59, pp.e03040-20~ (2021)
- Argueta EA, "Impact of antimicrobial resistance rates on eradication of Helicobacter pylori in a US population", Gastroenterology, 160, pp.2181~2183 (2021)
- Shiota S, "Antibiotic resistance of Helicobacter pylori among male United States veterans", Clin Gastroenterol Hepatol, 13, pp.1616~1624 (2015)
- Tan B, "Helicobacter pylori antimicrobial susceptibility testing-guided salvage therapy in the USA : a real life experience", Dig Dis Sci, 63, pp.437~445 (2018)
- Basu PP, "A randomized study comparing levofloxacin, omeprazole, nitazoxanide, and doxycycline versus triple therapy for the eradication of Helicobacter pylori", Am J Gastroenterol, 106, pp.1970~1975 (2011)
- Gisbert JP, "Review article : rifabutin in the treatment of refractory Helicobacter pylori infection", Aliment Pharmacol Ther, 35, pp.209~221 (2012)
- Miehlke S, "Randomized trial of rifabutin-based triple therapy and high-dose dual therapy for rescue treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin", Aliment Pharmacol Ther, 24, pp.395~403 (2006)
- Duck WM, "Antimicrobial resistance incidence and risk factors among Helicobacter pylori-infected persons, United States", Emerg Infect Dis, 10, pp.1088~1094 (2004)
- Bochenek WJ, "Eradication of Helicobacter pylori by 7-day triple-therapy regimens combining pantoprazole with clarithromycin, metronidazole, or amoxicillin in patients with peptic ulcer disease : results of two double-blind, randomized studies", Helicobacter, 8, pp.626~642 (2003)
- Laine L, "Esomeprazole-based Helicobacter pylori eradication therapy and the effect of antibiotic resistance : results of three US multicenter, doubleblind trials", Am J Gastroenterol, 95, pp.3393~3398 (2000)
- Magaret N, "A randomized trial of lansoprazole, amoxycillin, and clarithromycin versus lansoprazole, bismuth, metronidazole and tetracycline in the retreatment of patients failing initial Helicobacter pylori therapy", Dig Dis, 19, pp.174~178 (2001)